![\"ERA](\"http:\/\/www.afroditamc.com\/wp-content\/uploads\/2016\/08\/invitro11.jpg\")
<\/p>\n<\/p>\n
Personalized embryo transfer<\/strong><\/p>\n 1. What is the ERA test?<\/strong><\/p>\n The ERA test for the endometrial implantation window is an innovative diagnostic method developed\nand patented by IGENOMIX R&D after more than 10 years of research. This technique allows the\nevaluation of endometrial receptivity from a molecular point of view.<\/p>\n The ERA test for the endometrial implantation window is an innovative diagnostic method developed\nand patented by IGENOMIX R&D after more than 10 years of research. This technique allows the\nevaluation of endometrial receptivity from a molecular point of view.<\/p>\n Now, during the treatment process of an infertile couple, the ERA test provides an assessment of the\nendometrium at the molecular level and is a personalized genetic test to assess the state of\nendometrial receptivity in the implantation window.\nWhether the endometrium is receptive or not is determined after analyzing the expression of a\ngroup of genes. Endometrial biopsy should be performed on day P+5 (5 days after initiation of\nprogesterone in a cycle with hormone replacement therapy) or on day LH+7 (7 days after the\nluteinizing hormone peak in a spontaneous cycle). Once the sample is delivered, the expression of\n238 genes is analyzed. RNA from the endometrial tissue sample is hybridized with samples of these\ngenes. After hybridization, computer analysis classifies the sample as receptive or non-receptive\naccording to specific gene expression.<\/p>\n 2.Why is an ERA test done?<\/strong><\/p>\n Over 10 years of research and 3,000 clinical trials support this diagnostic method. The ERA test is\nused to assess the state of the endometrium and determine whether or not a patient's endometrium\nis receptive according to the genetic profile at the time the biopsy is performed.<\/p>\n The analysis reveals the timing of the implantation window and leads to personalized embryo\ntransfer (PET) and synchronization based on the individually obtained results.<\/p>\n The test result determines whether or not a woman's endometrium is receptive on the particular day\nand type of cycle in which the biopsy is performed. If she is receptive, this means that the\nimplantation window is on the day the biopsy is performed, and therefore the blastocyst can implant\non that day in this type of cycle.<\/p>\n If non-receptive, the result may indicate a displaced implantation window. Therefore, a second\nbiopsy will be required to determine this shift. According to the first result obtained, a specific day\nwill be suggested for the second biopsy. This gives a greater opportunity to carry out implantation in\nthe next cycle, through personalized embryo transfer (PET).<\/p>\n 3. In what cases is the ERA test used?<\/strong><\/p>\n The ERA test can determine whether a patient needs to customize the implantation window before\nstarting treatment. This diagnostic method has been tested in patients who have failed to implant\nembryos with good morphological characteristics and quality (at least three embryos in younger\nwomen or two in patients over 37). This test is recommended for women with normal parameters of\nthe uterus and with a normal thickness of the endometrium (\u22646mm), as well as the absence of\nreasons for infertility found during the examination. Displacement of the implantation window is\nfound in about 20% of these patients.<\/p>\n 4. What are the advantages of the test?<\/strong><\/p>\n As a diagnostic method to determine the receptivity of the endometrium, the ERA test determines\nthe window of implantation personalized for each individual patient before starting in vitro\ntreatment.<\/p>\n The ERA test shows high sensitivity and specificity in determining gene expression profiles associated\nwith receptivity.<\/p>\n The classic method for determining the state of the endometrium is based on histological criteria.\nThis previous diagnostic technique has been shown not to differentiate between fertile and infertile\npatients and is associated with a high degree of subjectivity, meaning that these results cannot be\napplied in clinical practice. The ERA test provides a solution to these problems.<\/p>\n 5.Frequently Asked Questions:<\/strong><\/p>\n \u041f\u0435\u0440\u0441\u043e\u043d\u0430\u043b\u0438\u0437\u0438\u0440\u0430\u043d \u0442\u0440\u0430\u043d\u0441\u0444\u0435\u0440 \u043d\u0430 \u0435\u043c\u0431\u0440\u0438\u043e\u043d\u0438 1.\u041a\u0430\u043a\u0432\u043e \u043f\u0440\u0435\u0434\u0441\u0442\u0430\u0432\u043b\u044f\u0432\u0430 ERA \u0442\u0435\u0441\u0442\u044a\u0442? ERA \u0442\u0435\u0441\u0442 \u0437\u0430 \u0438\u043c\u043f\u043b\u0430\u043d\u0442\u0430\u0446\u0438\u043e\u043d\u043d\u0438\u044f \u043f\u0440\u043e\u0437\u043e\u0440\u0435\u0446 \u043d\u0430 \u0435\u043d\u0434\u043e\u043c\u0435\u0442\u0440\u0438\u0443\u043c\u0430 – \u0442\u043e\u0432\u0430 \u0435 \u0438\u043d\u043e\u0432\u0430\u0442\u0438\u0432\u0435\u043d \u0434\u0438\u0430\u0433\u043d\u043e\u0441\u0442\u0438\u0447\u0435\u043d \u043c\u0435\u0442\u043e\u0434, \u0440\u0430\u0437\u0440\u0430\u0431\u043e\u0442\u0435\u043d \u0438 \u043f\u0430\u0442\u0435\u043d\u0442\u043e\u0432\u0430\u043d \u043e\u0442 IGENOMIX R&D \u0441\u043b\u0435\u0434 \u043f\u043e\u0432\u0435\u0447\u0435 \u043e\u0442 10 \u0433\u043e\u0434\u0438\u043d\u0438 \u0438\u0437\u0441\u043b\u0435\u0434\u0432\u0430\u043d\u0438\u044f. \u0422\u0430\u0437\u0438 \u0442\u0435\u0445\u043d\u0438\u043a\u0430 \u043f\u043e\u0437\u0432\u043e\u043b\u044f\u0432\u0430 \u0434\u0430 \u0441\u0435 \u043e\u0446\u0435\u043d\u0438 \u0432\u044a\u0437\u043f\u0440\u0438\u0435\u043c\u0447\u0438\u0432\u043e\u0441\u0442\u0442\u0430 \u043d\u0430 \u0435\u043d\u0434\u043e\u043c\u0435\u0442\u0440\u0438\u0443\u043c\u0430 \u043e\u0442 \u043c\u043e\u043b\u0435\u043a\u0443\u043b\u044f\u0440\u043d\u0430 \u0433\u043b\u0435\u0434\u043d\u0430 \u0442\u043e\u0447\u043a\u0430. ERA \u0442\u0435\u0441\u0442\u044a\u0442 \u043f\u043e\u043a\u0430\u0437\u0432\u0430 \u043f\u0440\u043e\u0437\u043e\u0440\u0435\u0446\u0430 \u043d\u0430 \u0438\u043c\u043f\u043b\u0430\u043d\u0442\u0430\u0446\u0438\u044f\u0442\u0430 (WOI), \u0443\u0432\u0435\u043b\u0438\u0447\u0430\u0432\u0430\u0439\u043a\u0438 \u0448\u0430\u043d\u0441\u043e\u0432\u0435\u0442\u0435… Continue reading ERA TEST DIAGNOSTIC METHOD<\/span><\/a><\/p>","protected":false},"author":2,"featured_media":0,"parent":2070,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"yoast_head":"\n\n
\nThe ERA test should be performed in either a\nstimulated or spontaneous cycle. The diagnosis of endometrial receptivity is valid only for the type of\ncycle in which the test is performed. Embryo transfer should therefore be performed in the same\ncycle type for which a positive receptivity result was obtained.<\/li>\n<\/ul>\n\n
\nA biopsy of the uterine fundus is performed according to a\nstandard procedure with a PipeIle catheter or similar. A sample of about 30 mg of tissue is sufficient\n(approximately the size of a cube with a side of 3 millimeters).<\/li>\n<\/ul>\n\n
\nStimulated cycle: When starting a stimulated cycle, the\nbiopsy is taken after five full days of progesterone (about 120 hours). The day of the first dose of\nprogesterone is considered day P+0, and the biopsy is done on day P+5.
\nSpontaneous cycle: The\nbiopsy is taken 7 days after the LH (luteinizing hormone) peak. The day of the LH peak is considered\nLH+0, the biopsy is done on day LH +7 (after about 168 hours). If ovulation is determined by\nultrasound, the day of ovulation is taken as day Ov+0, then the biopsy is done six days later\n(approximately 144 hours) on Ov+6.<\/li>\n<\/ul>\n\n
\nThe time of ovulation in spontaneous\ncycles can be determined using test strips for LH (luteinizing hormone) in urine, by direct\nmeasurement of LH in blood serum, or by observing follicular rupture on ultrasound examination.<\/li>\n<\/ul>\n\n
\nResult: "receptive"<\/strong>
\nIf the patient has frozen embryos or has fresh donor embryos, they can be\ntransferred in a cycle of the same type (stimulated or natural) for which a receptivity result was\nobtained. If blastocysts are to be transferred in a subsequent cycle, this is done on the same ordinal\nday on which the biopsy was performed in the previous cycle. If day 3 embryos are to be transferred,\nthis should be done two days before the biopsy from the previous cycle.
\nIf the patient does not have\nfrozen eggs or embryos and wants to use her own eggs, one cycle of ovarian stimulation should be\nperformed to cryopreserve eggs or embryos. Embryo transfer is performed in a subsequent cycle of\nthe same type (stimulated or spontaneous) for which an ERA test receptivity result is obtained.Result: "Non-receptive" (with recommendation for a new implantation window)<\/strong>
\nIf the result of the\nfirst ERA test is not positive and the analysis of the genetic profile indicates that the implantation\nwindow may be shifted, it is necessary to confirm this shift with a second ERA test. This second\nanalysis will determine the day on which the endometrium is receptive and, therefore, the thawing\nof embryos and their transfer should be planned according to this result.Result: "Non-receptive" (no recommendation for a new implantation window)<\/strong>
\nIf the result of the first\nERA test is not positive and the genetic profile analysis does not suggest a shifted implantation\nwindow, unfortunately, no therapeutic approach can be offered. This happens in less than 1% of\npatients.<\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"